Key result
The addition of eicosapentaenoic acid to strong statin therapy significantly reduced lipid volume in coronary plaques and decreased local inflammatory cytokines compared to statin therapy alone.
Why the study?
Does the addition of eicosapentaenoic acid to strong statin therapy improve coronary plaque components and reduce inflammatory cytokines in patients on strong statins?
RCT (n=95)
Open-label
Blocked-randomization
No
Does the addition of eicosapentaenoic acid to strong statin therapy improve coronary plaque components and reduce inflammatory cytokines in patients on strong statins?
Absolute Event Rate: -3.5% vs 1.5%
p-value: p=0.005
The addition of EPA to strong statin therapy favorably modifies coronary plaque composition by reducing lipid volume and increasing fibrous volume, while also decreasing local inflammatory cytokines.
No takes yet. Share an insight, caveat, or question.
Supports adding EPA to strong statins for plaque stabilization; extends RCT evidence on lipid and cytokine modulation.
Niki et al. (2015) conducted an RCT in Dyslipidemia with stable angina pectoris (n=95). Eicosapentaenoic acid (EPA) vs. No additional treatment (strong statin only) was evaluated on Nominal change in lipid volume (mm3) (p=0.005). The addition of eicosapentaenoic acid to strong statin therapy significantly reduced lipid volume in coronary plaques and decreased local inflammatory cytokines compared to statin therapy alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: